Search

Displaying results 2491 - 2500 of 6830 in total
  1. Drug

    Cocoa butter

    go.drugbank.com/drugs/DB11086
    Approved

    Dyslipidemia is characterized by elevated levels of plasma triglyceride and very-low-density lipoprotein (VLDL) cholesterol due to overproduction of large triglyceride-enriched VLDL cholesterol particles … Fat cocoa solids, including cocoa butter, have lower phenolic content than non-fat cocoa solids but may contain some polyphenols of different structures of flavonoids with antioxidant properties [A33041

  2. Drug

    Potassium bitartrate

    go.drugbank.com/drugs/DB11107
    ApprovedInvestigational

    Potassium bitartate, also referred to as potassium acid tartrate or cream of tartar, is the potassium acid salt of l-( + )-tartaric acid. … Potassium bitartrate was one of active ingredients in Phexxi, a non-hormonal contraceptive agent that was approved by the FDA on May 2020.[L14120]

    Mixtures: Ceo-two, Ceo-two Bowel Evacuant Suppositories
  3. Drug

    Pegaptanib

    go.drugbank.com/drugs/DB04895
    ApprovedWithdrawn

    Pegatinib aids neovascular age-related macular degeneration by binding to VEGF which in order reduces angiogenesis and vessel permeability. Pegaptanib was granted FDA approval on 17 September 2004.

  4. Drug

    Ramucirumab

    go.drugbank.com/drugs/DB05578
    ApprovedInvestigational

    By binding to VEGFR2, ramucirumab prevents binding of its ligands (VEGF-A, VEGF-C, and VEGF-D), thereby preventing VEGF-stimulated receptor phosphorylation and downstream ligand-induced proliferation, … In contrast to other agents directed against VEGFR-2, ramucirumab binds a specific epitope on the extracellular domain of VEGFR-2, thereby blocking all VEGF ligands from binding to it.

  5. Drug

    Eletriptan

    go.drugbank.com/drugs/DB00216
    ApprovedInvestigational

    Eletriptan is a second generation triptan drug developed by Pfizer Inc for the treatment of migraine headaches.

    Categories: Serotonergic Drugs Shown to Increase Risk of Serotonin Syndrome
  6. Drug

    Clonazepam

    go.drugbank.com/drugs/DB01068
    ApprovedIllicitInvestigational

    [FDA Label][A175438,L5572,F3763,F3787,F3796] The mechanism of action appears to involve the enhancement of gamma-aminobutyric acid receptor responses. … A benzodiazepine used to treat various seizures, including myotonic or atonic seizures, photosensitive epilepsy, and absence seizures, although tolerance may develop.

    Synonyms: 5-(o-chlorophenyl)-7-nitro-1,3-dihydro-2H-1,4-benzodiazepin-2-oneProducts: Co Clonazepam
  7. Drug

    Cabazitaxel

    go.drugbank.com/drugs/DB06772
    ApprovedInvestigational

    [A7056, A260421, A260621] Cabazitaxel is used to treat metastatic castration-resistant prostate cancer. It was first approved by the FDA on June 17, 2010. … [A7056] Due to its low affinity for the P-glycoprotein (P-gp) efflux pump, cabazitaxel can more readily penetrate the blood–brain barrier compared to other taxanes like [paclitaxel] and [docetaxel].

  8. Drug

    ALGRX 1207

    go.drugbank.com/drugs/DB06482
    Experimental

    ALGRX 1207 is a topical local anesthetic that acts by binding to the fast sodium channel. … It was being developed by Anesiva, but trials have halted.

  9. Drug

    Florquinitau (18F)

    go.drugbank.com/drugs/DB19215
    Approved

    [L64052] Florquinitau F 18, also known as MK-6240, was approved by the FDA on August 14, 2026 for PET of the brain in adults with cognitive impairment who are being evaluated for Alzheimer's disease … [L64052] It binds to aggregated tau protein, which in Alzheimer's disease forms the neurofibrillary tangles (NFTs) that are one of the two components required for a neuropathological diagnosis of the disease

  10. Drug

    Rusfertide

    go.drugbank.com/drugs/DB17724
    ApprovedInvestigational

    [L64098] Rusfertide is administered by subcutaneous injection and titrated to maintain hematocrit below 45%. … Rusfertide is a hepcidin mimetic used to treat erythrocytosis in adults with polycythemia vera.